Wen 2018.

Methods	Study design: Randomised clinical trial Study duration: March 2013 to March 2015 Duration of follow‐up: 2 years Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by pathology; huge HCC; tumour volume < 70% of whole liver volume; with liver function of Child‐Pugh Class A or B; ECOG ≤ 2 Exclusion criteria: With liver function of Child‐Pugh Class C; abnormal haematopoietic function; life expectancy < 6 months; with serious disease of other organs Age (mean ± SD): TACE + cryoablation: 53. 2 ± 12. 3 years; TACE alone: 54.8 ± 10.2 years Male (n/total): TACE + cryoablation: 35/43; TACE alone: 37/43 Vascular invasion (patients): TACE + cryoablation: 6; TACE: 4
Interventions	TACE + cryoablation group (n = 43): TACE: Chemotherapeutic drugs: lobaplatin Cryoablation: The interval between TACE and RFA was 1 week. Ultrasound‐guided cryoablation. TACE group (n = 43): Chemotherapeutic drugs: lobaplatin
Outcomes	Tumour response, classified as complete response, partial response, stable disease, and progression Adverse events 1‐ and 2‐year survival rates
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.